Equities

Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • Revenue in USD (TTM)52.47bn
  • Net income in USD9.87bn
  • Incorporated1942
  • Employees96.50k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttp://www.pfizer.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amgen, Inc.23.01bn8.18bn123.40bn19.20k15.353.8312.055.3611.0711.0731.1644.360.29041.456.981,198,542.0010.329.0211.7010.3082.2880.7735.5429.055.7218.520.526135.466.148.0911.2815.968.1048.17
AbbVie Inc27.27bn6.65bn149.22bn30.00k22.6222.3418.405.474.144.1416.964.190.40273.715.52909,100.009.8212.4011.7316.4076.7677.4424.3821.091.329.820.849756.6612.168.0115.7311.646.14--
Merck & Co., Inc.39.80bn2.85bn150.55bn68.00k53.513.9319.993.781.031.0314.4714.030.4191.795.29585,352.903.026.093.717.5176.4272.637.2114.641.1618.030.412283.340.7823-3.69-11.75-8.93-1.303.90
Pfizer Inc.52.47bn9.87bn210.83bn96.50k21.723.4713.054.021.631.638.6310.200.29931.455.29543,740.905.655.016.915.9378.7380.2618.8916.991.1514.770.418378.728.13-2.853.58-1.641.218.45
Data as of Nov 17 2017. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

24.98%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2017415.18m6.98%
SSgA Funds Management, Inc.as of 30 Sep 2017309.18m5.20%
BlackRock Fund Advisorsas of 30 Sep 2017276.15m4.64%
Northern Trust Investments, Inc.as of 30 Sep 201781.08m1.36%
JPMorgan Investment Management, Inc.as of 30 Sep 201777.22m1.30%
Managed Account Advisors LLCas of 30 Sep 201771.27m1.20%
Wellington Management Co. LLPas of 30 Sep 201770.31m1.18%
T. Rowe Price Associates, Inc.as of 30 Sep 201762.15m1.05%
Massachusetts Financial Services Co.as of 30 Sep 201761.66m1.04%
Geode Capital Management LLCas of 30 Sep 201761.24m1.03%
More ▼
Data from 30 Sep 2017 - 30 Sep 2017Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.